Tolerancia del tratamiento con interferón estándar y ribavirina en pacientes cirróticos por virus de la hepatitis C

in treatment of compensating hepatic cirrhosis of viral etiology the maintained viral response with interferon and ribavirin is minor and it is accompanied of a greater frequency of adverse effects in relation to non-cirrhotic patients. however, due to the scarce therapeutical options for this group of patients and the need to retard the appearance of complications, was the reason of present paper. authors present the results from a group of 36 patients diagnosed with hepatic cirrhosis from hcv in a child's stage included in multicenter clinical trials, sponsored by the institute of gastroenterology; patients received a therapeutical scheme of interferon alfa-2b plus ribavirin during 48 weeks assessing their tolerance by clinical and hematologic adverse events. results demonstrate that this treatment alternative is safe and well-tolerated.